Talk:4F-ADB

From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: 4F-ADB
4F-ADB
4F-ADB.svg
Chemical Nomenclature
Common names 4F-ADB
Substitutive name 4-Fluoro ADB,
Systematic name methyl-(2S)-2-{[1-(4-Fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate
Class Membership
Psychoactive class Cannabinoid
Chemical class Indazolecarboxamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.












DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions


4F-ADB (also known as 4-Fluoro ADB, 4F-MDMB-BUTINACA, 4F-MDMB-BINACA) is a synthetic cannabinoid substance of the indazolecarboxamide class.

Subjective effects are reported to be somewhat similar to that of cannabis with a short duration and an emphasis on intense physical sensations.

Cannabinoids are commonly smoked or vaporized to achieve a quick onset of effects and rapid offset. 4F-ADB is orally active when dissolved in a lipid, which can increase the duration significantly. Like other cannabinoids, it is insoluble in water but dissolves in ethanol and lipids.

Unlike cannabis, the chronic abuse of synthetic cannabinoids has been associated with multiple serious injuries deaths and more dangerous side effects and toxicity in general. Therefore, it is strongly discouraged to take this substance for extended periods of time or in excessive doses.

Chemistry

4F-ADB has the structure methyl (2S)-2-{[1-(4-Fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate.[1] It is a positional isomer of 5F-ADB, and is an analogue of MDMB-PINACA (aka ADB) with an additional fluorine atom.

It is a synthetic indazolecarboxamide as it contains a substituted indazole group. This indazole moeity is substituted at R1 with a 4-fluoropentyl chain. This is a positional isomer of the fluoropentyl substitution of cannabinoids such as 5F-AKB48 and 5F-PB-22. Additionally, the indazole is substituted at R3 with a carboxamide group. This carboxamide group is N-substituted at its terminal amine group with a dimethylbutanoate group. This substitution is shared with MDMB-FUBINACA and 5-Cl-ADB-A.

Pharmacology

Although this substance has not been formally studied, from analysis of the structure, it is presumed that 5F-AKB48 has a similar binding profile to that of other cannabinoids and matches many of the in vivo properties of Δ9-THC. Like other indazole synthetic cannabinoids, it is likely to be a full agonist of the CB1 receptor. This is distinct from phytocannabinoids such as THC, which are partial agonists.

Toxicity and harm potential

The toxicity and long-term health effects of recreational 4F-ADB use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 4F-ADB has very little history of human usage.

It has often been recommended that those with severe pre-existing mental conditions should not ingest these substances due to the way they strongly increase one's current state of mind and emotions. Also, like THC, prolonged usage of synthetic cannabinoids including $F-ADB may increase one's disposition to mental illness and psychosis[2], particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).[3][4][5]

As synthetic cannabinoids are active in the milligram range (with below 5mg being a common dose), it is important to use proper precautions when dosing to avoid a negative experience. It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

As with other synthetic cannabinoids, the chronic use of 4F-ADB can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 4F-ADB develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 4F-ADB presents cross-tolerance with all cannabinoids, meaning that after the consumption of 4F-ADB all cannabinoids will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • 2C-T-x
  • 2C-x
  • 5-MeO-xxT
  • Amphetamines - Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  • aMT
  • Cocaine - Stimulants increase anxiety levels and the risk of thought loops which can lead to negative experiences
  • DMT
  • DOx
  • Lithium - Lithium is commonly prescribed in the treatment of bipolar disorder; however, there is a large body of anecdotal evidence that suggests taking it with cannabinoids can significantly increase the risk of psychosis and seizures. As a result, this combination should be strictly avoided.
  • LSD
  • Mescaline
  • Mushrooms
  • 25x-NBOMe

Legal status

Handcuffs-300px.png

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

See also

External links

References

  1. Explore 4F-ADB | PiHKAL.info
  2. Causal association between cannabis and psychosis: examination of the evidence - The British Journal of Psychiatry Jan 2004, 184 (2) 110-117 | http://bjp.rcpsych.org/content/184/2/110.short
  3. Every-Palmer, S. Synthetic cannabinoid use and psychosis: an explorative study. Journal of Drug and Alcohol Dependence 2011.
  4. “Spice” Girls: Synthetic Cannabinoid Intoxication - The Journal of Emergency Medicine Volume 40, Issue 3, March 2011, Pages 296–299 (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0736467910008802
  5. A Teenager With Agitation: Higher Than She Should Have Climbed - Pediatric Emergency Care: June 2010 - Volume 26 - Issue 6 - pp 462-465 | http://journals.lww.com/pec-online/Abstract/2010/06000/A_Teenager_With_Agitation__Higher_Than_She_Should.16.aspx